Guangzhou Wondfo Biotech Co Ltd (300482) - Net Assets

Latest as of March 2026: CN¥5.58 Billion CNY ≈ $816.21 Million USD

Based on the latest financial reports, Guangzhou Wondfo Biotech Co Ltd (300482) has net assets worth CN¥5.58 Billion CNY (≈ $816.21 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.73 Billion ≈ $985.42 Million USD) and total liabilities (CN¥1.16 Billion ≈ $169.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300482 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥5.58 Billion
% of Total Assets	82.83%
Annual Growth Rate	29.63%
5-Year Change	56.21%
10-Year Change	540.37%
Growth Volatility	31.44

Guangzhou Wondfo Biotech Co Ltd - Net Assets Trend (2011–2025)

This chart illustrates how Guangzhou Wondfo Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Guangzhou Wondfo Biotech Co Ltd to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Guangzhou Wondfo Biotech Co Ltd (2011–2025)

The table below shows the annual net assets of Guangzhou Wondfo Biotech Co Ltd from 2011 to 2025. For live valuation and market cap data, see Guangzhou Wondfo Biotech Co Ltd (300482) total market value.

Year	Net Assets	Change
2025-12-31	CN¥5.47 Billion ≈ $800.95 Million	-3.13%
2024-12-31	CN¥5.65 Billion ≈ $826.81 Million	+22.44%
2023-12-31	CN¥4.61 Billion ≈ $675.26 Million	+1.70%
2022-12-31	CN¥4.54 Billion ≈ $663.99 Million	+29.49%
2021-12-31	CN¥3.50 Billion ≈ $512.76 Million	+17.05%
2020-12-31	CN¥2.99 Billion ≈ $438.06 Million	+21.66%
2019-12-31	CN¥2.46 Billion ≈ $360.06 Million	+14.37%
2018-12-31	CN¥2.15 Billion ≈ $314.82 Million	+80.80%
2017-12-31	CN¥1.19 Billion ≈ $174.13 Million	+39.22%
2016-12-31	CN¥854.75 Million ≈ $125.08 Million	+22.00%
2015-12-31	CN¥700.64 Million ≈ $102.53 Million	+123.54%
2014-12-31	CN¥313.43 Million ≈ $45.86 Million	+29.80%
2013-12-31	CN¥241.47 Million ≈ $35.33 Million	+32.32%
2012-12-31	CN¥182.48 Million ≈ $26.70 Million	+26.19%
2011-12-31	CN¥144.61 Million ≈ $21.16 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guangzhou Wondfo Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 3892.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥3.30 Billion	60.87%
Other Components	CN¥2.12 Billion	39.13%
Total Equity	CN¥5.41 Billion	100.00%

Guangzhou Wondfo Biotech Co Ltd Competitors by Market Cap

The table below lists competitors of Guangzhou Wondfo Biotech Co Ltd ranked by their market capitalization.

Company	Market Cap
Yelp Inc NYSE:YELP	$1.39 Billion
Crombie Real Estate Investment Trust TO:CRR-UN	$1.39 Billion
Land and Houses Public Company Limited BK:LH	$1.39 Billion
STAAR Surgical Company NASDAQ:STAA	$1.39 Billion
Med Life SA RO:M	$1.38 Billion
Electrolux Professional AB (publ) ST:EPRO-B	$1.38 Billion
China Express Airlines Co Ltd Class A SHE:002928	$1.38 Billion
Gansu Jiu Steel Group Hongxing Iron & Steel Co Ltd SHG:600307	$1.38 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guangzhou Wondfo Biotech Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,554,388,042 to 5,414,625,996, a change of -139,762,046 (-2.5%).
Net loss of 63,024,900 reduced equity.
Dividend payments of 197,637,372 reduced retained earnings.
Other comprehensive income increased equity by 21,291,598.
Other factors increased equity by 99,608,628.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥-63.02 Million	-1.16%
Dividends Paid	CN¥197.64 Million	-3.65%
Other Comprehensive Income	CN¥21.29 Million	+0.39%
Other Changes	CN¥99.61 Million	+1.84%
Total Change	CN¥-	-2.52%

Book Value vs Market Value Analysis

This analysis compares Guangzhou Wondfo Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.75x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 43.53x to 1.75x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	CN¥0.46	CN¥20.22	x
2012-12-31	CN¥0.59	CN¥20.22	x
2013-12-31	CN¥0.78	CN¥20.22	x
2014-12-31	CN¥1.01	CN¥20.22	x
2015-12-31	CN¥1.93	CN¥20.22	x
2016-12-31	CN¥2.04	CN¥20.22	x
2017-12-31	CN¥2.48	CN¥20.22	x
2018-12-31	CN¥4.45	CN¥20.22	x
2019-12-31	CN¥5.04	CN¥20.22	x
2020-12-31	CN¥6.44	CN¥20.22	x
2021-12-31	CN¥7.56	CN¥20.22	x
2022-12-31	CN¥9.83	CN¥20.22	x
2023-12-31	CN¥10.19	CN¥20.22	x
2024-12-31	CN¥11.97	CN¥20.22	x
2025-12-31	CN¥11.57	CN¥20.22	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guangzhou Wondfo Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -1.16%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -3.02%
• Asset Turnover: 0.32x
• Equity Multiplier: 1.22x
Recent ROE (-1.16%) is below the historical average (18.40%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	21.91%	17.27%	0.70x	1.81x	CN¥17.21 Million
2012	20.77%	16.67%	0.75x	1.66x	CN¥19.66 Million
2013	24.43%	23.83%	0.74x	1.39x	CN¥34.86 Million
2014	31.38%	26.92%	0.89x	1.31x	CN¥67.02 Million
2015	17.89%	29.23%	0.54x	1.14x	CN¥55.29 Million
2016	17.21%	26.49%	0.54x	1.19x	CN¥60.72 Million
2017	20.48%	18.39%	0.68x	1.65x	CN¥107.80 Million
2018	15.91%	18.65%	0.61x	1.39x	CN¥114.30 Million
2019	17.43%	18.70%	0.70x	1.32x	CN¥165.13 Million
2020	22.31%	22.56%	0.65x	1.52x	CN¥349.94 Million
2021	18.92%	18.88%	0.69x	1.45x	CN¥299.12 Million
2022	27.56%	21.07%	0.90x	1.45x	CN¥762.69 Million
2023	10.80%	17.64%	0.48x	1.28x	CN¥36.03 Million
2024	10.11%	18.33%	0.43x	1.29x	CN¥6.19 Million
2025	-1.16%	-3.02%	0.32x	1.22x	CN¥-604.49 Million

Industry Comparison

This section compares Guangzhou Wondfo Biotech Co Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $1,869,358,268
Average return on equity (ROE) among peers: 12.87%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guangzhou Wondfo Biotech Co Ltd (300482)	CN¥5.58 Billion	21.91%	0.21x	$1.38 Billion
Shanghai Kehua Bio-Engineering Co Ltd (002022)	$1.03 Billion	22.10%	0.17x	$369.55 Million
Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)	$482.51 Million	20.84%	0.32x	$3.70 Billion
Double Medical Technology Inc (002901)	$2.13 Billion	28.38%	0.24x	$2.52 Billion
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)	$242.93 Million	26.96%	0.06x	$505.95 Million
Lepu Medical Tech Beijing (300003)	$8.00 Billion	21.55%	0.99x	$3.16 Billion
INKON Life Technology Co Ltd (300143)	$1.37 Billion	-51.44%	0.43x	$761.10 Million
Edan Instruments Inc (300206)	$1.22 Billion	8.49%	0.19x	$1.15 Billion
Guangdong Biolight Meditech Co Ltd (300246)	$992.38 Million	6.43%	0.73x	$717.10 Million
Beijing Leadman Biochemistry Co Ltd (300289)	$83.90 Million	31.18%	0.36x	$466.49 Million
Sinocare Inc (300298)	$3.14 Billion	14.20%	0.47x	$1.19 Billion

About Guangzhou Wondfo Biotech Co Ltd

SHE:300482 China Medical Devices

Market Cap

$1.38 Billion

CN¥9.46 Billion CNY

Market Cap Rank

#7713 Global

#1806 in China

Share Price

CN¥20.22

Change (1 day)

-2.46%

52-Week Range

CN¥16.07 - CN¥25.56

All Time High

CN¥92.01